Founders / Clarissa Desjardins
Congruence Therapeutics
Computationally driven drug discovery using its Revenir platform (biophysics and machine learning) to design small-molecule correctors for protein-misfolding diseases.
- Role
- Co-founder/CEO
- HQ
- Montréal, QC
- Founded
- 2021
- Status
- Active
- Disclosed raised
- US$71.5M
- Latest round
- Undisclosed, Mar 19, 2026
Investors: Dimension, OrbiMed, Amplitude Ventures, Fonds de solidarité FTQ, Lumira Ventures, Investissement Québec, BDC Thrive Venture Fund, Driehaus Capital Management, and 2 more
Founders are listed as named in primary coverage of their companies. Profile links are matched to the company before they are published. To correct this page or ask for it to be removed, email the Index.
Data as of September 29, 2026.